PURPOSE: To date, there is no effective therapy for triple-negative breast cancer (TNBC), which has a dismal clinical outcome. Upregulation of tissue factor (TF) expression leads to increased patient morbidity and mortality in many solid tumor types, including TNBC. Our goal was to employ the Fab fragment of ALT-836, a chimeric anti-human TF mAb, for PET imaging of TNBC, which can be used to guide future TNBC therapy. METHODS: ALT-836-Fab was generated by enzymatic papain digestion. SDS-PAGE and FACS studies were performed to evaluate the integrity and TF binding affinity of ALT-836-Fab before NOTA conjugation and (64)Cu-labeling. Serial PET imaging and biodistribution studies were carried out to evaluate the tumor targeting efficacy and pharmacokinetics in the MDA-MB-231 TNBC model, which expresses high levels of TF on the tumor cells. Blocking studies, histological assessment, as well as RT-PCR were performed to confirm TF specificity of (64)Cu-NOTA-ALT-836-Fab. RESULTS: ALT-836-Fab was produced with high purity, which exhibited superb TF binding affinity and specificity. Serial PET imaging revealed rapid and persistent tumor uptake of (64)Cu-NOTA-ALT-836-Fab (5.1 ± 0.5 %ID/g at 24 h post-injection; n = 4) and high tumor/muscle ratio (7.0 ± 1.2 at 24 h post-injection; n = 4), several-fold higher than that of the blocking group and tumor models that do not express significant level of TF, which was confirmed by biodistribution studies. TF specificity of the tracer was also validated by histology and RT-PCR. CONCLUSION: (64)Cu-NOTA-ALT-836-Fab exhibited prominent tissue factor targeting efficiency in MDA-MB-231 TNBC model. The use of a Fab fragment led to fast tumor uptake and good tissue/muscle ratio, which may be translated into same-day immunoPET imaging in the clinical setting to improve TNBC patient management.
PURPOSE: To date, there is no effective therapy for triple-negative breast cancer (TNBC), which has a dismal clinical outcome. Upregulation of tissue factor (TF) expression leads to increased patient morbidity and mortality in many solid tumor types, including TNBC. Our goal was to employ the Fab fragment of ALT-836, a chimeric anti-humanTF mAb, for PET imaging of TNBC, which can be used to guide future TNBC therapy. METHODS:ALT-836-Fab was generated by enzymatic papain digestion. SDS-PAGE and FACS studies were performed to evaluate the integrity and TF binding affinity of ALT-836-Fab before NOTA conjugation and (64)Cu-labeling. Serial PET imaging and biodistribution studies were carried out to evaluate the tumor targeting efficacy and pharmacokinetics in the MDA-MB-231 TNBC model, which expresses high levels of TF on the tumor cells. Blocking studies, histological assessment, as well as RT-PCR were performed to confirm TF specificity of (64)Cu-NOTA-ALT-836-Fab. RESULTS:ALT-836-Fab was produced with high purity, which exhibited superb TF binding affinity and specificity. Serial PET imaging revealed rapid and persistent tumor uptake of (64)Cu-NOTA-ALT-836-Fab (5.1 ± 0.5 %ID/g at 24 h post-injection; n = 4) and high tumor/muscle ratio (7.0 ± 1.2 at 24 h post-injection; n = 4), several-fold higher than that of the blocking group and tumor models that do not express significant level of TF, which was confirmed by biodistribution studies. TF specificity of the tracer was also validated by histology and RT-PCR. CONCLUSION: (64)Cu-NOTA-ALT-836-Fab exhibited prominent tissue factor targeting efficiency in MDA-MB-231 TNBC model. The use of a Fab fragment led to fast tumor uptake and good tissue/muscle ratio, which may be translated into same-day immunoPET imaging in the clinical setting to improve TNBC patient management.
Authors: Anton G T Terwisscha van Scheltinga; Paul Berghuis; Hilde H Nienhuis; Hetty Timmer-Bosscha; Linda Pot; Sietske B M Gaykema; Marjolijn N Lub-de Hooge; Jos G W Kosterink; Elisabeth G E de Vries; Carolien P Schröder Journal: Eur J Cancer Date: 2014-07-12 Impact factor: 9.162
Authors: Richard S Finn; Judy Dering; Charles Ginther; Cindy A Wilson; Padraic Glaspy; Nishan Tchekmedyian; Dennis J Slamon Journal: Breast Cancer Res Treat Date: 2007-02-01 Impact factor: 4.872
Authors: Hakan Orbay; Yin Zhang; Hao Hong; Timothy A Hacker; Hector F Valdovinos; James A Zagzebski; Charles P Theuer; Todd E Barnhart; Weibo Cai Journal: Mol Pharm Date: 2013-06-17 Impact factor: 4.939
Authors: Sixiang Shi; Tingting Li; Xiaofei Wen; Sherry Y Wu; Chiyi Xiong; Jun Zhao; Victor R Lincha; Diana S Chow; Yiyao Liu; Anil K Sood; Chun Li Journal: Bioconjug Chem Date: 2019-09-27 Impact factor: 4.774
Authors: Bai Liu; Lin Kong; Kaiping Han; Hao Hong; Warren D Marcus; Xiaoyue Chen; Emily K Jeng; Sarah Alter; Xiaoyun Zhu; Mark P Rubinstein; Sixiang Shi; Peter R Rhode; Weibo Cai; Hing C Wong Journal: J Biol Chem Date: 2016-09-20 Impact factor: 5.157
Authors: Reinier Hernandez; Haiyan Sun; Christopher G England; Hector F Valdovinos; Todd E Barnhart; Yunan Yang; Weibo Cai Journal: Mol Pharm Date: 2016-06-10 Impact factor: 4.939